The overall aim of OPERAM (OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly) is to optimise existing pharmacological and non-pharmacological therapy primarily in order to reduce avoidable hospital admissions among the elderly population aged ≥70 years with multimorbidity.
Specifically, the OPERAM consortium aims at:
- Creating new evidence to prevent avoidable hospital admissions through optimising pharmacotherapy in the multimorbid elderly by performing a multi-centre cluster randomised clinical trial (RCT) to assess the impact of a structured medication review
- Obtaining evidence-based data comparing pharmacological and non-pharmacological interventions to prevent common causes of avoidable hospital admissions in the elderly with multimorbidity, and rank these interventions according to their effectiveness and safety using network meta-analyses (NMA)
- Identify the most cost-effective pharmacological and non-pharmacological interventions to prevent avoidable hospital admissions in the multimorbid elderly
COMPAR-EU is a multimethod, inter-disciplinary project that will contribute to bridging the gap between current knowledge and practice of self-management interventions. COMPAR-EU aims to identify, compare, and rank the most effective and cost-effective self-management interventions (SMIs) for adults in Europe living with one of the four high-priority chronic conditions: type 2 diabetes, obesity, chronic obstructive pulmonary disease, and heart failure. The project will provide support for policymakers, guideline developers and professionals to make informed decisions on the adoption of the most suitable self-management interventions through an IT platform, featuring decision-making tools adapted to the needs of a wide range of end users (including researchers, patients, and industry).
Completed Projects We Participated
2013 – 2016
GetReal is a three-year project of the Innovative Medicines Initiative (IMI), a EU public-private consortium consisting of pharmaceutical companies, academia, HTA agencies and regulators (e.g., NICE, HAS, EMA and ZIN), patient organisations and SMEs. GetReal aims to show how robust new methods of RWE collection and synthesis could be adopted earlier in pharmaceutical R&D and the healthcare decision making process.
2010 – 2015
Integrating Multiple Meta-Analysis (IMMA) into health care praxis and research is a framework for establishing, disseminating and integrating the ‘second-generation’ meta-analysis toolkit.